Pieris Pharma (PIRS) Reports In-Line Q2 Loss

August 10, 2016 5:01 PM EDT
Get Alerts PIRS Hot Sheet
Trade PIRS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Pieris Pharma (NASDAQ: PIRS) reported Q2 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $1.07 million versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Pieris Pharma (PIRS) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment